Therapeutic innovation is increasingly driven by academic researchers and small companies, who are rapidly translating exciting advances in basic research into new therapies. These innovators often lack access to experienced drug developers and GMP manufacturing capacity. This can make development of advanced therapies such as cell and gene therapy challenging, since process and product definition are often intertwined. Such therapies require integrated process and product development to ensure the technologies employed are scalable and robust for commercialization. Landmark Bio aims to break down the barriers in novel modality development and industrialization by providing innovators with access to drug development and Chemistry Manufacturing and Controls (CMC) expertise and capabilities. Landmark’s flexible labs and GMP manufacturing spaces support a diverse technology toolbox for bring new advanced therapies to the clinic. This talk will highlight examples of how Landmark has enabled clients to advance a variety of novel therapies.